CTL works diligently with Cornell researchers and innovators by bringing their inventions from the lab to the marketplace. As Cornell’s technology commercialization office, we are exploring new ways to create business opportunities, launching new ventures, and helping to commercialize Cornell technologies. Learn more about CTL’s annual activities and metrics.
Commercializing
109
Licenses & Options
FY2020-2024:
477 Licenses & Options
$22 M
Revenue Generated
FY2020-2024:
$122M Revenue Generated
Venturing
10
New Startups Based on Cornell IP
$418.6 M
Funding Raised by Startups in FY24
- Neuralenz
- Kubbly
- BiaWear
- Anova Biomedical
- Astoria Biologica
- Carbon to Stone
- ExoPower
- Giant Biosystems
- Graphenode
- Sacyl Pharmaceuticals
FY2020-2024:
$2.3B Funding Raised by Startups
Protecting
169
US Non-Provisional Patent Applications
| Filed Location | 2020 | 2021 | 2022 | 2023 | 2024 |
| U.S. Provisional | 158 | 163 | 163 | 164 | 143 |
| U.S. Nonprovisional | 195 | 179 | 164 | 169 | 169 |
| International | 322 | 304 | 318 | 217 | 251 |
| Total | 675 | 646 | 645 | 550 | 544 |
107
US Issued Patents
| FY | 2020 | 2021 | 2022 | 2023 | 2024 |
| U.S. | 124 | 127 | 79 | 104 | 107 |
| International | 284 | 191 | 142 | 117 | 144 |
| Total | 408 | 318 | 221 | 221 | 251 |
Ideating
34
Educational Programs Offered
70
Office Hours
313
IP Disclosures
Recent News
TETmedical, Inc. announced that the U.S. FDA has granted Breakthrough Device Designation to its NSE-FAST® (Neuron Specific Enolase — Functional Activity Stroke Test).
The Center for Technology Licensing brought together Cornell inventors in Ithaca and at Weill Cornell Medicine for Bearers of Innovation: A One Cornell Celebration, recognizing those who have disclosed a…
Kanvas Biosciences is taking a major step forward in microbiome therapeutics with the announcement of $48 million in Series A funding.
NPSeal was developed at Weill Cornell Medicine and spun out as Guard Medical, Inc., founded in 2018 and recently acquired.
